Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In an embodiment the glass composition may include from about 67 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; from about 2 mol. % to about 10 mol. % Al2O3; from about 2 mol. % to about 18 mol. % alkali oxide, wherein the alkali oxide comprises non-zero amounts of Na2O; from 0 mol. % to about 4 mol. % B2O3; and from about 0.01 mol. % to about 1 mol. % of a fining agent.

Abstract: A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.

Abstract: A glass article may include SiO2, Al2O3, B2O3, at least one alkali oxide, and at least one alkaline earth oxide. The glass article may be capable of being strengthened by ion exchange. The glass article has a thickness t. The concentration(s) of the constituent components of the glass may be such that: 13?0.0308543*(188.5+((23.84*Al2O3)+(?16.97*B2O3)+(69.10*Na2O)+(?213.3*K2O))+((Na2O?7.274)*(?7.3628)+(Al2O3?2.863)*(K2O?0.520)*(321.5)+(B2O3?9.668)*(K2O?0.520)*(?39.74)))/t.

Abstract: A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.

Abstract: A glass article may include SiO2, Al2O3, B2O3, at least one alkali oxide, and at least one alkaline earth oxide. The glass article may be capable of being strengthened by ion exchange. The glass article has a thickness t. The concentration(s) of the constituent components of the glass may be such that: 13?0.0308543*(188.5+((23.84*Al2O3)+(?16.97*B2O3)+(69.10*Na2O)+(?213.3*K2O))+((Na2O?7.274)2*(?7.3628)+(Al2O3?2.863)*(K2O?0.520)*(321.5)+(B2O3?9.668)*(K2O?0.520)*(?39.74)))/t.

Abstract: A method of making a glass sheet comprises laminating a high CTE core glass to a low CTE clad glass at high temperatures and allowing the laminate to cool creating compressive stress in the clad glass, and then ion exchanging the laminate to increase the compressive stress in the outer near surface regions of the clad glass. The core glass may include ions that exchange with ion in the clad glass to increase the compressive stress in inner surface regions of the clad glass adjacent to the clad glass/core glass interfaces. The glass laminate may be formed and laminated using a fusion forming and laminating process and fusion formable and ion exchangeable glass compositions.

Abstract: Embodiments of glass containers resistant to delamination and methods for forming the same are disclosed. According to one embodiment, a delamination resistant glass container may include a glass article having a body extending between an interior surface and an exterior surface. The body defines an interior volume. The body may include an interior region extending from 10 nm below the interior surface of the body into a thickness of the body. The interior region has a persistent layer homogeneity such that the body is resistant to delamination.

Abstract: A strengthened glass container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The strengthened glass container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.

Abstract: A method of making a glass sheet comprises laminating a high CTE core glass to a low CTE clad glass at high temperatures and allowing the laminate to cool creating compressive stress in the clad glass, and then ion exchanging the laminate to increase the compressive stress in the outer near surface regions of the clad glass. The core glass may include ions that exchange with ion in the clad glass to increase the compressive stress in inner surface regions of the clad glass adjacent to the clad glass/core glass interfaces. The glass laminate may be formed and laminated using a fusion forming and laminating process and fusion formable and ion exchangeable glass compositions.

Abstract: Intermediate to high CTE glass compositions and laminates formed from the same are described. The glasses described herein have properties, such as liquidus viscosity or liquidus temperature, which make them particularly well suited for use in fusion forming processes, such as the fusion down draw process and/or the fusion lamination process. Further, the glass composition may be used in a laminated glass article, such as a laminated glass article formed by a fusion laminate process, to provide strengthened laminates via clad compression as a result of CTE mismatch between the core glass and clad glass.

Abstract: A method of making a glass container for storing a pharmaceutical formulation includes heating a Type 1 glass composition according to ASTM Standard E438-92 (2011) to form a glass melt, and forming the glass melt into a glass tube. The glass tube is then re-formed into the glass container having a glass body with: a wall region with an interior surface and an exterior surface; a heel region; and a base region. The interior surface of the glass container is formed by the interior surface of the glass body. A glass pharmaceutical container has a CDR value of less than or equal to 6.0, at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719, and Type 1 chemical durability according to USP <660>.

Abstract: A method including obtaining glass containers, and adding a solvent to 5.0% by volume to less than or equal to 50.0% by volume. Heating to an elevated temperature and cooling to room temperature. The solvent is consolidated and titrated, where an amount of a titrant is an as received titrant volume. Glass containers are etched, and a second solvent is added at 8.0% by volume to less than or equal to 25.0% by volume. The containers are heated to an elevated temperature and cooled to room temperature. The second solvent is consolidated and titrated, where an amount of a titrant is an etched titrant volume. The Chemical Durability Ratio (CDR) of the plurality of glass containers is calculated where: CDR = As ? ? Received ? ? Titrant ? ? Volume Etched ? ? Titrant ? ? Volume .

Abstract: A glass container for storing pharmaceutical formulations may include a glass body formed from a Type IA or Type IB glass composition according to ASTM Standard E438-92(2011). The glass body may include a wall portion with an inner surface and an outer surface, a heel portion and a floor portion, wherein the inner surface of the glass container is formed by the inner surface of the glass body. The glass body may include at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. The glass container does not comprise a boron-rich layer on the inner surface of the glass body in as formed condition.

Abstract: Glass pharmaceutical packages comprising glass containers are disclosed. In embodiments, a coated glass pharmaceutical package includes a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A lubricous coating may be positioned on at least a portion of the exterior surface of the glass container. The portion of the coated glass pharmaceutical package with the lubricous coating has a coefficient of friction that is at least 20% less than an uncoated glass container formed from the same glass composition. A horizontal compression strength of the portion of the coated glass pharmaceutical package with the lubricous coating may be at least 10% greater than an uncoated glass container formed from the same glass composition.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 ?m. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

Abstract: A delamination resistant glass pharmaceutical container may include a glass body comprising a borosilicate glass having a Type 1 chemical durability according to USP <660>. At least an inner surface of the glass body may have a delamination factor less than or equal to 10. A thermally stable coating may be positioned around at least a portion of the outer surface of the glass body. The thermally stable coating may be an outermost coating on the outer surface of the glass body and the outer surface of the glass body with the thermally stable coating has a coefficient of friction less than or equal to 0.7. The thermally stable coating comprising at least one of a metal nitride coating, a metal oxide coating, a metal sulfide coating, SiO2, diamond-like carbon, graphene, and a carbide coating.

Abstract: In embodiments, a glass composition may include: greater than or equal to 71 mol. % and less than or equal to 83 mol. % SiO2; greater than or equal to 1 mol. % and less than or equal to 11 mol. % Al2O3; greater than or equal to 5 mol. % and less than or equal to 18 mol. % alkali oxide, the alkali oxide comprising greater than 3 mol. % Li2O and at least one of Na2O and K2O; greater than or equal to 1 mol. % and less than or equal to 8 mol. % alkaline earth oxide, the alkaline earth oxide comprising MgO and at least one of CaO, BaO, and SrO; and at least one of TiO2, ZrO2, HfO2, La2O3 and Y2O3, wherein TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than 0 mol. % and less than or equal to 6 mol. % and Al2O3+TiO2+ZrO2+HfO2+La2O3+Y2O3 is greater than or equal to 2 mol. % and less than or equal to 12 mol. %.

Abstract: A glass article includes a glass core layer and a glass cladding layer adjacent to the core layer. An average coefficient of thermal expansion (CTE) of the core layer is greater than an average CTE of the cladding layer. An effective 109.9 P temperature of the glass article is at most about 750° C.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.